Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17886030rdf:typepubmed:Citationlld:pubmed
pubmed-article:17886030lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:17886030lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:17886030lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:17886030lifeskim:mentionsumls-concept:C0005775lld:lifeskim
pubmed-article:17886030lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:17886030lifeskim:mentionsumls-concept:C0751982lld:lifeskim
pubmed-article:17886030lifeskim:mentionsumls-concept:C1956394lld:lifeskim
pubmed-article:17886030pubmed:issue10lld:pubmed
pubmed-article:17886030pubmed:dateCreated2007-9-21lld:pubmed
pubmed-article:17886030pubmed:abstractTextThioredoxin-1 (TRX) is a redox-active protein with anti-inflammatory effects. This study investigated the optimal delivery method and the mechanisms of recombinant human TRX (rhTRX) to suppress neutrophil recruitment in a rat bleomycin (BLM)-induced sustained acute lung injury model. In male Wister rats intratracheally administered with 0.125 mg/kg BLM, 8 mg/kg/day rhTRX was intravenously administered on days 3-6 using one of three protocols: daily bolus injection, 3 h daily infusion or continuous infusion for 96 h. Only the continuous-infusion of rhTRX significantly reduced the neutrophil infiltration compared with the other two methods. The BLM-induced down-regulation of L-selectin expression on circulating neutrophils was inhibited by rhTRX. Oxidized rhTRX showed a comparable effect with reduced rhTRX and rhTRX incubated with plasma or circulating in plasma was more than 99% oxidized. These results suggest that rhTRX becomes oxidized in circulation and continuous infusion of rhTRX suppresses neutrophil recruitment in the airway.lld:pubmed
pubmed-article:17886030pubmed:languageenglld:pubmed
pubmed-article:17886030pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:citationSubsetIMlld:pubmed
pubmed-article:17886030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17886030pubmed:statusMEDLINElld:pubmed
pubmed-article:17886030pubmed:monthOctlld:pubmed
pubmed-article:17886030pubmed:issn1071-5762lld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:UedaShugoSlld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:YodoiJunjiJlld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:NakamuraTakay...lld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:WadaHiromiHlld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:YamadaAkiraAlld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:NakamuraHajim...lld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:OkuyamaHiroak...lld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:HoshinoYumaYlld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:TerataniAkieAlld:pubmed
pubmed-article:17886030pubmed:authorpubmed-author:FurukawaSuzuy...lld:pubmed
pubmed-article:17886030pubmed:issnTypePrintlld:pubmed
pubmed-article:17886030pubmed:volume41lld:pubmed
pubmed-article:17886030pubmed:ownerNLMlld:pubmed
pubmed-article:17886030pubmed:authorsCompleteYlld:pubmed
pubmed-article:17886030pubmed:pagination1089-98lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:meshHeadingpubmed-meshheading:17886030...lld:pubmed
pubmed-article:17886030pubmed:year2007lld:pubmed
pubmed-article:17886030pubmed:articleTitleRecombinant human thioredoxin-1 becomes oxidized in circulation and suppresses bleomycin-induced neutrophil recruitment in the rat airway.lld:pubmed
pubmed-article:17886030pubmed:affiliationThioredoxin Project, Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.lld:pubmed
pubmed-article:17886030pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17886030pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed